Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

This study (called LuPARPed) tests a combination of a targeted radiation therapy called 177Lu-DOTATATE (Lutathera) with a drug called olaparib (a PARP inhibitor) in children and teenagers with solid tumors that have come back or are not responding to treatment. The tumors must have a specific protein on their surface (somatostatin receptors) that the Lutathera drug can target. **You may be eligible if...** - Your child is between 3 and 18 years old at the time of enrollment (and was at least 18 months old at initial diagnosis) - They have a relapsed or treatment-resistant solid tumor - The tumor shows uptake on a special scan (SSTR-PET), confirming the presence of the target protein - The SSTR-PET scan was done within the past 3 months **You may NOT be eligible if...** - The tumor does not show active uptake on the SSTR-PET scan - The child is under 3 years old at the time of enrollment - Other medical conditions make the treatment combination unsafe Talk to your doctor to see if this trial is right for you.